Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO ANNOUNCES USFDA FILING FOR SOFOSBUVIR TABLETS, 400MG01-03-2018
01-03-2018
Natco: Stock correction an opportunity as earnings trajectory remains firm
Natco Pharma, which was one of the few outperformers in the pharma pack until recently, has seen its share price fall by a fourth since its January highs of Rs 1,050 levels. While the launch of its mega blockbuster product, Copaxone generics (oncology treatment) in the US was among key reasons for earlier gains, some disappointment in the December quarter results (Q3) coupled with weakness in broader markets has contributed to the recent correction. Nevertheless, this fall offers an opportunity to investors given the company's strong future prospects, say analysts.To begin with, Natco's revenues fell 16 per cent year-on-year to Rs 5.6 billion in Q3, mainly due to the high base of last year which had seen large contribution from another mega product Tamiflu generic (anti-viral drug for flu treatment) launched on exclusivity basis. Analysts also attribute the miss in revenues to subdued performance of Hepatitis-C business in India and partly due to lower-than-expected revenue...23-02-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajeev Nannapaneni22-02-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
USFDA COMPLETES INSPECTION OF NATCO's MEKAGUDA API FACILITY WITH ZERO OBSERVATIONS17-02-2018
Natco Pharma falls on news of routine FDA inspection, short-term outlook good for the firm
Natco Pharma investors are jittery about the stock after lower than expected results in Q3, and today the share price for the company fell after it said that its facility in Mekaguda was undergoing a routine FDA inspection. Overall: Weaker results, and competition for gCopaxone The company's weaker earnings in Q3 can be attributed to the lag in profit share booking from generic Copaxone and Tamiflu suspension opportunities in the US. It was also affected by a 25% decline in HCV franchise QoQ. Analysts predict that the gap will be made up in Q4. And growth is likely to continue in FY19, once we take a clear-eyed look at the balance sheet: Copaxone generic will log a full year of sales, and bosentan and imatinib should add to the sales numbers. Longer-term however, Natco is facing challenges. Competition is building fast in the generics space, aided by FDA policies encouraging more players in each drug to bring down prices for patients. Generic Copaxone is one of those drugs where large players are threatening Natco's revenues.The company is boosting its domestic growth in a bid to counter the potential revenue losses from US competition. But that is not going to be enough - Natco will have to use its profits and cash flow today to drive more launches, and build a drug platform that is more resistent to competition. It will also have to double down on marketing efforts in the US market as players attempt to take bites of its market share. It is hard to predict how Natco will perform here, since it hasn't faced an aggressive pricing environment previously in its most profitable drugs. Consequently while FY19 looks healthy for the company, its hard to predict what lies further ahead for Natco.14-02-2018
Clarification
With reference to news flashed on ET Now dated February 14, 2018 quoting "USFDA inspection at co's Mekaguda facility in Telangana underway", Natco Pharma Ltd has submitted to BSE a copy of Clarification is enclosed.14-02-2018
Clarification sought from Natco Pharma Ltd
The Exchange has sought clarification from Natco Pharma Ltd on February 14, 2018 with reference to news flashed on ET Now dated February 14, 2018 quoting "USFDA inspection at co's Mekaguda facility in Telangana underway".The reply is awaited.14-02-2018
Limited Review Report for December 31, 2017
Natco Pharma Ltd has informed BSE about : 1. Consolidated Limited Review for the period ended December 31, 201713-02-2018
Top Losers on Volume: Natco Pharma tops the list amid caution on FY19 sales
Natco Pharma had reported a 11.54% rise in its consolidated profit after tax at Rs 217.4 crore for the quarter ended December 2017. FY18 according to the company looks strong overall. Natco expects near Rs 300 crore of profits in the final quarter - this is typically a strong quarter for Natco Pharma due to flu season driving sales of the company's generic Tamiflu in the United States. However, Natco is among the top losers on high volumes today following comments from the company's management. Natco Pharma management is cautious about FY19, despite the launch of its generic version of multiple-sclerosis drug Copaxone. Natco in its earnings call said that is seeing significant competition in the 20 mg and 40 mg versions of the Copaxone drug - two players are launching generic versions of the drug in the United States market, which may impact Natoc's 15% market share in the 40 mg generic. For the full screener, click here.07-02-2018